এই ওষুধে সাশ্রয় করুন
একই সক্রিয় উপাদানের অন্যান্য ব্র্যান্ড
এই ব্র্যান্ডগুলোতে একই সক্রিয় উপাদান আছে (Brigatinib). Strength ও ফর্ম আলাদা হতে পারে — পরিবর্তনের আগে আপনার ডাক্তার বা ফার্মাসিস্টের সাথে বিকল্প ওষুধটি নিশ্চিত করে নিন।
ইঙ্গিত ও ব্যবহার
Briganix 30 এর জন্য নির্দেশিত:
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
প্রাপ্তবয়স্ক:
The recommended dosing regimen for Brigatinib is: 90 mg orally once daily for the first 7 days; If 90 mg is tolerated during the first 7 days, the dose should be increased to 180 mg orally once daily. Brigatinib should be administered until disease progression or unacceptable toxicity. If Brigatinib is interrupted for 14 days or longer for reasons other than adverse reactions, treatment should be resumed at 90 mg once daily for 7 days before increasing to the previously tolerated dose. Brigatinib may be taken with or without food. Patients should be instructed to swallow tablets whole. Tablets should not be crushed or chewed. If a dose of Brigatinib is missed or vomiting occurs after taking a dose, an additional dose should not be administered and take the next dose of Brigatinib should be taken at the scheduled time.Pediatric Use: The safety and efficacy of Brigatinib in pediatric patients have not been established.
পার্শ্বপ্রতিক্রিয়া
Interstitial Lung Disease (ILD)/Pneumonitis Hypertension Bradycardia Visual Disturbance Creatine Phosphokinase (CPK) Elevation Pancreatic Enzyme Elevation Hyperglycemia
সতর্কতা ও নিষেধাজ্ঞা
সতর্কতা ও সাবধানতা
Interstitial Lung Disease (ILD)/Pneumonitis: Severe, life-threatening, and fatal pulmonary adverse reactions consistent with interstitial lung disease (ILD)/pneumonitis have occurred with Brigacent. It should be withheld in any patient with new or worsening respiratory symptoms, and promptly evaluate for ILD/pneumonitis or other causes of respiratory symptoms (e.g., pulmonary embolism, tumor progression, and infectious pneumonia). Brigacent should be discontinued permanently for Grade 3 or 4 ILD/pneumonitis or recurrence of Grade 1 or 2 ILD/pneumonitis.Hypertension: Hypertension was reported in 11% of patients in the 90 mg group who received Brigacent and 21% of patients in the 90-180 mg group. Grade 3 hypertension occurred in 5.9% of patients overall. Blood pressure should be controlled prior to treatment with Brigacent. Blood pressure should be monitored after 2 weeks and at least monthly thereafter during treatment with Brigacent. It should be withheld for Grade 3 hypertension despite optimal antihypertensive therapy. Permanent discontinuation of treatment should be considered with Brigacent for Grade 4 hypertension or recurrence of Grade 3 hypertension. Caution should be used when administering Brigacent in combination with antihypertensive agents that cause bradycardia.Bradycardia: Bradycardia can occur with Brigacent. Heart rate and blood pressure should be monitored during treatment with Brigacent. Patients should be monitored more frequently if concomitant use of drug known to cause bradycardia cannot be avoided.Visual Disturbance: Adverse reactions leading to visual disturbance including blurred vision, diplopia, and reduced visual acuity, were reported in 7.3% of patients receiving Brigacent in the 90 mg group and 10% of patients in the 90-180 mg group. Patients should be advised to report any visual symptoms. Brigacent should be withheld and obtained an ophthalmologic evaluation in patients with new or worsening visual symptoms of Grade 2 or greater severity. Upon recovery of Grade 2 or Grade 3 visual disturbances to Grade 1 severity or baseline, Brigacent should be resumed at a reduced dose. Treatment with Brigacent should be permanently discontinued for Grade 4 visual disturbances.Creatine Phosphokinase (CPK) Elevation: Creatine phosphokinase (CPK) elevation occurred in 27% of patients receiving Brigacent in the 90 mg group and 48% of patients in the 90 mg-180 mg group. Patients should be advised to report any unexplained muscle pain, tenderness, or weakness. CPK levels should be monitored during Brigacent treatment. Brigacent should be withheld for Grade 3 or 4 CPK elevation.Pancreatic Enzyme Elevation: Amylase elevation occurred in 27% of patients in the 90 mg group and 39% of patients in the 90→180 mg group. Lipase elevations occurred in 21% of patients in the 90 mg group and 45% of patients in the 90→180 mg group. Lipase and amylase should be monitored during treatment with Brigacent. Brigacent should be withheld for Grade 3 or 4 pancreatic enzyme elevation. Hyperglycemia: 43% of patients who received Brigacent experienced new or worsening hyperglycemia. Grade 3 hyperglycemia, based on laboratory assessment of serum fasting glucose levels, occurred in 3.7% of patients. Two of 20 (10%) patients with diabetes Brigacent or glucose intolerance at baseline required initiation of insulin while receiving Brigacent. Fasting serum glucose should be assessed prior to initiation of Brigacent and monitored periodically thereafter. Antihyperglycemic medications should be initiated or optimized as needed. If adequate hyperglycemic control cannot be achieved with optimal medical management, Brigacent should be withheld until adequate hyperglycemic control is achieved and considered reducing the dose of Brigacent.
নিষেধাজ্ঞা
It is contraindicated in patients with known hypersensitivity to Brigatinib or any other components of this product.